NDA 203202 · Lundbeck Na LTD
Northera
Droxidopa · Oral
NovelAccelerated approvalPriority reviewOrphanLast checked: Nov 20, 2026Latest source record: Feb 10, 2017 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
2014
Feb 18, 2014
Approved uses
1
Original approval plus efficacy supplements
Registered trials
40
9 Phase 3, 3 recruiting
FAERS reports
21,553
8,359 serious, 2,843 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
Boxed warning
WARNING: SUPINE HYPERTENSION Monitor supine blood pressure prior to and during treatment and more frequently when increasing doses. Elevating the head of the bed lessens the risk of supine hypertension, and blood pressure should be measured in this position. If supine hypertension cannot be managed by elevation of the head of the bed, reduce or discontinue NORTHERA [see Warnings and Precautions ( 5.1 )]. WARNING: SUPINE HYPERTENSION See full prescribing information for complete boxed warning. Monitor supine blood pressure prior to and during treatment and more frequently when increasing doses. Elevating the head of the bed lessens the risk of supine hypertension, and blood pressure should be measured in this position. If supine hypertension cannot be managed by elevation of the head of the bed, reduce or discontinue NORTHERA [see Warnings and Precautions ( 5.1 )].
What it is approved for
From the label in effect Jul 1, 2019.
NORTHERA is indicated for the treatment of orthostatic dizziness, lightheadedness, or the “feeling that you are about to black out” in adult patients with symptomatic neurogenic orthostatic hypotension (nOH) caused by primary autonomic failure (Parkinson's disease [PD], multiple system atrophy, and pure autonomic failure), dopamine beta-hydroxylase deficiency, and non-diabetic autonomic neuropathy. Effectiveness beyond 2 weeks of treatment has not been established. The continued effectiveness of NORTHERA should be assessed periodically. NORTHERA is indicated for the treatment of orthostatic dizziness, lightheadedness, or the “feeling that you are about to black out” in adult patients with symptomatic neurogenic orthostatic hypotension (nOH) caused by primary autonomic failure (Parkinson's disease [PD], multiple system atrophy, and pure autonomic failure), dopamine beta-hydroxylase deficiency, and non-diabetic autonomic neuropathy. Effectiveness beyond 2 weeks of treatment has not been established. The continued effectiveness of NORTHERA should be assessed periodically ( 1 ).
Mechanism: The exact mechanism of action of NORTHERA in the treatment of neurogenic orthostatic hypotension is unknown. NORTHERA is a synthetic amino acid analog that is directly metabolized to norepinephrine by dopa-decarboxylase, which is extensively distributed throughout the body. NORTHERA is believed to exert its pharmacological effects through norepinephrine and not through the parent molecule or other metabolites. Norepinephrine increases blood pressure by inducing peripheral arterial and venous vasoconstriction. NORTHERA in humans induces small and transient rises in plasma norepinephrine.
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
- Feb 18, 2014 Original approval · Type 1 - New Molecular Entity · priority review NovelAccelerated approvalOrphanLabelLetterReview
3 products under this application
- NORTHERA · DROXIDOPA 200MG · CAPSULE, ORAL · Prescription · TE AB
- NORTHERA · DROXIDOPA 300MG · CAPSULE, ORAL · Prescription · TE AB
- NORTHERA · DROXIDOPA 100MG · CAPSULE, ORAL · Prescription · TE AB
Clinical trials
Interventional ClinicalTrials.gov studies with "Droxidopa" as an intervention, any sponsor and status, largest first.
- Sustained Effect of Droxidopa in Symptomatic Neurogenic Orthostatic HypotensionPivotal-lookingCompleted
H. Lundbeck A/SIndustry
NCT02586623 · 453 participants · Start Feb 11, 2016 · Primary completion Jul 21, 2022
Drug: Droxidopa capsules; Placebo capsules · For: Symptomatic Neurogenic Orthostatic Hypotension
Sites: Chandler, Arizona; Phoenix, Arizona; Scottsdale, Arizona · 168 sites in all
- Clinical Study of Droxidopa in Patients With Neurogenic Orthostatic Hypotension (NOH) (Droxi-304)Pivotal-lookingCompleted
Chelsea TherapeuticsIndustry
NCT01132326 · 350 participants · Start Jan 2009 · Primary completion Feb 2013
Drug: Droxidopa · For: Primary Autonomic Failure; Dopamine Beta Hydroxylase Deficiency; Non-Diabetic Neuropathy and 1 more
- A Clinical Study for Patients With Neurogenic Orthostatic Hypotension (NOH) Using DroxidopaPivotal-lookingCompleted
Chelsea TherapeuticsIndustry
NCT00782340 · 263 participants · Start Sep 2008 · Primary completion Sep 2010
Drug: Placebo; Droxidopa · For: Symptomatic Neurogenic Orthostatic Hypotension (NOH); Non-diabetic Neuropathy; Primary Autonomic Failure and 1 more
Sites: Huntsville, Alabama; Scottsdale, Arizona; Little Rock, Arkansas · 21 sites in all
- A Two Part Study (306A/306B) to Assess Droxidopa in Treatment of NOH in Patients With Parkinson's DiseasePivotal-lookingCompleted
Chelsea TherapeuticsIndustry
NCT01176240 · 225 participants · Start Jun 2010 · Primary completion Oct 2012
Drug: Droxidopa · For: Orthostatic Hypotension; Parkinson's Disease
Sites: Alabaster, Alabama; Gilbert, Arizona; Phoenix, Arizona · 60 sites in all
- Clinical Study of Droxidopa in Patients With Neurogenic Orthostatic Hypotension (NOH)Pivotal-lookingCompleted
Chelsea TherapeuticsIndustry
NCT00633880 · 181 participants · Start Jan 2008 · Primary completion Aug 2009
Drug: Placebo; Droxidopa · For: Symptomatic Neurogenic Orthostatic Hypotension (NOH); Non-diabetic Neuropathy; Primary Autonomic Failure and 1 more
Sites: Birmingham, Alabama; Litchfield Park, Arizona; Phoenix, Arizona · 54 sites in all
- Study To Assess The Clinical Benefit Of Droxidopa And Droxidopa/Carbidopa In Subjects With FibromyalgiaPivotal-lookingCompleted
Chelsea TherapeuticsIndustry
NCT01323374 · 122 participants · Start Jan 2009 · Primary completion Oct 2011
Drug: Droxidopa; Carbidopa and 2 more · For: Fibromyalgia
Sites: Barnsley, United Kingdom; Liverpool, United Kingdom; London, United Kingdom · 7 sites in all
- Efficacy of L-threo DOPS on Orthostatic Hypotension Symptoms and Other Non-motor Symptoms in Patients With MSAPivotal-lookingCompleted
University Hospital, ToulouseAcademic, hospital or other
NCT02071459 · 107 participants · Start Jan 21, 2014 · Primary completion Oct 28, 2019
Drug: L-Threo DOPS; placebo · For: Multiple System Atrophy
Sites: Angers, France; Bordeaux, France; Clermont-Ferrand, France · 13 sites in all
- Open-Label Clinical Study of Droxidopa in Patients With Neurogenic Orthostatic Hypotension (NOH)Pivotal-lookingCompleted
Chelsea TherapeuticsIndustry
NCT00738062 · 103 participants · Start Jan 2008 · Primary completion Dec 2010
Drug: Droxidopa; Placebo · For: Neurogenic Orthostatic Hypotension; Non-Diabetic Autonomic Neuropathy; Multiple System Atrophy and 1 more
Sites: Birmingham, Alabama; Litchfield Park, Arizona; Phoenix, Arizona · 54 sites in all
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- dizziness2,924
- death2,201
- blood pressure increased1,886
- drug ineffective1,674
- headache1,589
- fall1,521
- hypotension1,268
- fatigue1,203
- hypertension1,153
- nausea1,070
- blood pressure decreased1,016
- drug dose omission958
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2004 | 6 |
| 2005 | 4 |
| 2006 | 8 |
| 2007 | 5 |
| 2008 | 5 |
| 2009 | 6 |
| 2010 | 4 |
| 2011 | 2 |
| 2012 | 15 |
| 2013 | 6 |
| 2014 | 169 |
| 2015 | 2,362 |
| 2016 | 3,714 |
| 2017 | 4,065 |
| 2018 | 3,508 |
| 2019 | 2,034 |
| 2020 | 2,274 |
| 2021 | 1,495 |
| 2022 | 453 |
| 2023 | 422 |
| 2024 | 365 |
| 2025 | 359 |
| 2026 | 272 |
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Part D: Northera (Droxidopa)
2024 spending
$19.1M
Beneficiaries
181
1,060 claims
Per beneficiary
$105,383
$87.82 per unit
View as table
| Year | Spending |
|---|---|
| 2020 | $240,811,642 |
| 2021 | $88,688,954 |
| 2022 | $37,962,360 |
| 2023 | $27,885,155 |
| 2024 | $19,074,267 |
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Long-term safety of droxidopa in patients with symptomatic neurogenic orthostatic hypotension.
Isaacson S, Vernino S, Ziemann A, et al. · J Am Soc Hypertens 2016 · Clinical Trial, Phase III, Multicenter Study
- Droxidopa for orthostatic hypotension: a systematic review and meta-analysis.
Strassheim V, Newton JL, Tan MP, et al. · J Hypertens 2016 · Meta-Analysis, Systematic Review
- Droxidopa for the short-term treatment of symptomatic neurogenic orthostatic hypotension in Parkinson's disease (nOH306B).
Hauser RA, Isaacson S, Lisk JP, et al. · Mov Disord 2015 · Clinical Trial, Phase III, Multicenter Study
- Droxidopa in patients with neurogenic orthostatic hypotension associated with Parkinson's disease (NOH306A).
Hauser RA, Hewitt LA, Isaacson S · J Parkinsons Dis 2014 · Clinical Trial, Phase III, Multicenter Study
- Meta-analysis of the safety and efficacy of droxidopa for neurogenic orthostatic hypotension.
Elgebaly A, Abdelazeim B, Mattar O, et al. · Clin Auton Res 2016 · Meta-Analysis, Review
- Prevention and Management of Supine Hypertension in Patients With Orthostatic Hypotension.
Moroi MK, Ruzieh M, Ahmed A, et al. · Am J Ther 2021 · Systematic Review
Sponsor: Lundbeck Na LTD
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.